Late Glacial to Holocene relative sea-level change in Assynt, northwest Scotland, UK

Relative sea-level change (RSL), from the Late Glacial through to the late Holocene, is reconstructed for the Assynt region, northwest Scotland, based on bio- and lithostratigraphical analysis. Four new radiocarbon-dated sea-level index points help constrain RSL change for the Late Glacial to the late Holocene. These new data, in addition to published material, capture the RSL fall during the Late Glacial and the rise and fall associated with the mid-Holocene highstand. Two of these index points constrain the Late Glacial RSL history in Assynt for the first time, reconstructing RSL falling from 2.47 ± 0.59 m OD to 0.15 ± 0.59 m OD at c. 14,000–15,000 cal yr BP. These new data test model predictions of glacial isostatic adjustment (GIA), particularly during the early deglacial period which is currently poorly constrained throughout the British Isles. Whilst the empirical data from the mid- to late-Holocene to present matches quite well with the recent GIA model output, there is a relatively poor fit between the timing of the Late Glacial RSL fall and early Holocene RSL rise. This mismatch, also evident elsewhere in northwest Scotland, may result from uncertainties associated with both the global and local ice components of GIA models.</jats:p

Missing sea level rise in southeastern Greenland during and since the Little Ice Age

The Greenland Ice Sheet has been losing mass at an accelerating rate over the past 2 decades. Understanding ice mass and glacier changes during the preceding several hundred years prior to geodetic measurements is more difficult because evidence of past ice extent in many places was later overridden. Salt marshes provide the only continuous records of relative sea level (RSL) from close to the Greenland Ice Sheet that span the period of time during and since the Little Ice Age (LIA) and can be used to reconstruct ice mass gain and loss over recent centuries. Salt marsh sediments collected at the mouth of Dronning Marie Dal, close to the Greenland Ice Sheet margin in southeastern Greenland, record RSL changes over the past ca. 300 years through changing sediment and diatom stratigraphy. These RSL changes record a combination of processes that are dominated by local and regional changes in Greenland Ice Sheet mass balance during this critical period that spans the maximum of the LIA and 20th-century warming. In the early part of the record (1725–1762 CE) the rate of RSL rise is higher than reconstructed from the closest isolation basin at Timmiarmiut, but between 1762 and 1880 CE the RSL rate is within the error range of the rate of RSL change recorded in the isolation basin. RSL begins to slowly fall around 1880 CE, with a total amount of RSL fall of 0.09±0.1 m in the last 140 years. Modelled RSL, which takes into account contributions from post-LIA Greenland Ice Sheet glacio-isostatic adjustment (GIA), ongoing deglacial GIA, the global non-ice sheet glacial melt fingerprint, contributions from thermosteric effects, the Antarctic mass loss sea level fingerprint and terrestrial water storage, overpredicts the amount of RSL fall since the end of the LIA by at least 0.5 m. The GIA signal caused by post-LIA Greenland Ice Sheet mass loss is by far the largest contributor to this modelled RSL, and error in its calculation has a large impact on RSL predictions at Dronning Marie Dal. We cannot reconcile the modelled RSL and the salt marsh observations, even when moving the termination of the LIA to 1700 CE and reducing the post-LIA Greenland mass loss signal by 30 %, and a “budget residual” of  mm yr−1 since the end of the LIA remains unexplained. This new RSL record backs up other studies that suggest that there are significant regional differences in the timing and magnitude of the response of the Greenland Ice Sheet to the climate shift from the LIA into the 20th century

Quantifying the Uncertainty in the Eurasian Ice-Sheet Geometry at the Penultimate Glacial Maximum (Marine Isotope Stage 6)

North Sea Last Interglacial sea level is sensitive to the fingerprint of mass loss from polar ice sheets. However, the signal is complicated by the influence of glacial isostatic adjustment driven by the Penultimate Glacial Period Eurasian ice sheet and its geometry remain significantly uncertain. Here, we produce new reconstructions of the Eurasian ice sheet during the Penultimate Glacial Maximum (PGM), for use as input to sea-level and climate models, by employing large ensemble experiments from a simple ice-sheet model that depends solely on basal sheer stress, ice extent, and topography. To explore the range of uncertainty in possible ice geometries, we use a parameterised shear-stress map as input that has been developed to incorporate bedrock characteristics and ice-sheet basal processes. We perform Bayesian uncertainty quantification to calibrate against global ice-sheet reconstructions of the last deglaciation to rule out combinations of input parameters that produce unrealistic ice sheets. The refined parameter space is then applied to the PGM to create an ensemble of plausible 3D Eurasian ice-sheet geometries. Our reconstructed PGM Eurasian ice-sheet volume is 51.16&plusmn;6.13 m sea-level equivalent which suggests a 14.3 % reduction in the volume of the PGM Laurentide ice-sheet. We find that the Barents-Kara Sea region displays both the largest mean volume and relative variability of 26.80 &plusmn; 3.58 m SLE while the British-Irish sector&rsquo;s volume of 1.77 &plusmn; 0.11 m SLE is smallest, yet most implausible. Our new workflow may be applied to other locations and periods where ice-sheet histories have limited empirical data.</p

Organic carbon stocks of Great British saltmarshes

Coastal wetlands, such as saltmarshes, are globally widespread and highly effective at capturing and storing ‘blue carbon’ and have the potential to regulate climate over varying timescales. Yet only Australia and the United States of America have national inventories of organic carbon held within saltmarsh habitats, hindering the development of policies and management strategies to protect and preserve these organic carbon stores. Here we couple a new observational dataset with 4,797 samples from 26 saltmarshes across Great Britain to spatially model organic carbon stored in the soil and the above and belowground biomass of Great British saltmarshes. Using average values derived from the 26 marshes, we deliver first-order estimates of organic carbon stocks across Great Britain’s 448 saltmarshes (451.66 km2). The saltmarshes of Great Britain contain 5.20 ± 0.65 Mt of organic carbon, 93% of which is in the soil. On average, the saltmarshes store 11.55 ± 1.56 kg C m-2 with values ranging between 2.24 kg C m-2 and 40.51 kg C m-2 depending on interlinked factors such as geomorphology, organic carbon source, sediment type (mud vs sand), sediment supply, and relative sea level history. These findings affirm that saltmarshes represent the largest intertidal blue carbon store in Great Britain, yet remain an unaccounted for component of the United Kingdom’s natural carbon stores

Palaeo-sea-level and palaeo-ice-sheet databases: problems, strategies, and perspectives

Sea-level and ice-sheet databases have driven numerous advances in understanding the Earth system. We describe the challenges and offer best strategies that can be adopted to build self-consistent and standardised databases of geological and geochemical information used to archive palaeo-sea-levels and palaeo-ice-sheets. There are three phases in the development of a database: (i) measurement, (ii) interpretation, and (iii) database creation. Measurement should include the objective description of the position and age of a sample, description of associated geological features, and quantification of uncertainties Interpretation of the sample may have a subjective component, but it should always include uncertainties and alternative or contrasting interpretations, with any exclusion of existing interpretations requiring a full justification. During the creation of a database, an approach based on accessibility, transparency, trust, availability, continuity, completeness, and communication of content (ATTAC³) must be adopted. It is essential to consider the community that creates and benefits from a database. We conclude that funding agencies should not only consider the creation of original data in specific research question-oriented projects, but also include the possibility of using part of the funding for IT -related and database creation tasks, which are essential to guarantee accessibility and maintenance of the collected data

Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study

Background: The impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on postoperative recovery needs to be understood to inform clinical decision making during and after the COVID-19 pandemic. This study reports 30-day mortality and pulmonary complication rates in patients with perioperative SARS-CoV-2 infection. Methods: This international, multicentre, cohort study at 235 hospitals in 24 countries included all patients undergoing surgery who had SARS-CoV-2 infection confirmed within 7 days before or 30 days after surgery. The primary outcome measure was 30-day postoperative mortality and was assessed in all enrolled patients. The main secondary outcome measure was pulmonary complications, defined as pneumonia, acute respiratory distress syndrome, or unexpected postoperative ventilation. Findings: This analysis includes 1128 patients who had surgery between Jan 1 and March 31, 2020, of whom 835 (74·0%) had emergency surgery and 280 (24·8%) had elective surgery. SARS-CoV-2 infection was confirmed preoperatively in 294 (26·1%) patients. 30-day mortality was 23·8% (268 of 1128). Pulmonary complications occurred in 577 (51·2%) of 1128 patients; 30-day mortality in these patients was 38·0% (219 of 577), accounting for 81·7% (219 of 268) of all deaths. In adjusted analyses, 30-day mortality was associated with male sex (odds ratio 1·75 [95% CI 1·28–2·40], p\textless0·0001), age 70 years or older versus younger than 70 years (2·30 [1·65–3·22], p\textless0·0001), American Society of Anesthesiologists grades 3–5 versus grades 1–2 (2·35 [1·57–3·53], p\textless0·0001), malignant versus benign or obstetric diagnosis (1·55 [1·01–2·39], p=0·046), emergency versus elective surgery (1·67 [1·06–2·63], p=0·026), and major versus minor surgery (1·52 [1·01–2·31], p=0·047). Interpretation: Postoperative pulmonary complications occur in half of patients with perioperative SARS-CoV-2 infection and are associated with high mortality. Thresholds for surgery during the COVID-19 pandemic should be higher than during normal practice, particularly in men aged 70 years and older. Consideration should be given for postponing non-urgent procedures and promoting non-operative treatment to delay or avoid the need for surgery. Funding: National Institute for Health Research (NIHR), Association of Coloproctology of Great Britain and Ireland, Bowel and Cancer Research, Bowel Disease Research Foundation, Association of Upper Gastrointestinal Surgeons, British Association of Surgical Oncology, British Gynaecological Cancer Society, European Society of Coloproctology, NIHR Academy, Sarcoma UK, Vascular Society for Great Britain and Ireland, and Yorkshire Cancer Research

Finishing the euchromatic sequence of the human genome

The sequence of the human genome encodes the genetic instructions for human physiology, as well as rich information about human evolution. In 2001, the International Human Genome Sequencing Consortium reported a draft sequence of the euchromatic portion of the human genome. Since then, the international collaboration has worked to convert this draft into a genome sequence with high accuracy and nearly complete coverage. Here, we report the result of this finishing process. The current genome sequence (Build 35) contains 2.85 billion nucleotides interrupted by only 341 gaps. It covers ∼99% of the euchromatic genome and is accurate to an error rate of ∼1 event per 100,000 bases. Many of the remaining euchromatic gaps are associated with segmental duplications and will require focused work with new methods. The near-complete sequence, the first for a vertebrate, greatly improves the precision of biological analyses of the human genome including studies of gene number, birth and death. Notably, the human enome seems to encode only 20,000-25,000 protein-coding genes. The genome sequence reported here should serve as a firm foundation for biomedical research in the decades ahead

A prenylated dsRNA sensor protects against severe COVID-19

Inherited genetic factors can influence the severity of COVID-19, but the molecular explanation underpinning a genetic association is often unclear. Intracellular antiviral defenses can inhibit the replication of viruses and reduce disease severity. To better understand the antiviral defenses relevant to COVID-19, we used interferon-stimulated gene (ISG) expression screening to reveal that OAS1, through RNase L, potently inhibits SARS-CoV-2. We show that a common splice-acceptor SNP (Rs10774671) governs whether people express prenylated OAS1 isoforms that are membrane-associated and sense specific regions of SARS-CoV-2 RNAs, or only express cytosolic, nonprenylated OAS1 that does not efficiently detect SARS-CoV-2. Importantly, in hospitalized patients, expression of prenylated OAS1 was associated with protection from severe COVID-19, suggesting this antiviral defense is a major component of a protective antiviral response

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

BACKGROUND: A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. METHODS: This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. FINDINGS: Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0-75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4-97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8-80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3-4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. INTERPRETATION: ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials. FUNDING: UK Research and Innovation, National Institutes for Health Research (NIHR), Coalition for Epidemic Preparedness Innovations, Bill & Melinda Gates Foundation, Lemann Foundation, Rede D'Or, Brava and Telles Foundation, NIHR Oxford Biomedical Research Centre, Thames Valley and South Midland's NIHR Clinical Research Network, and AstraZeneca